Document is current
Any future updates will be listed below
-
Authors
van Kessel, Sebastiaan P. https://orcid.org/0000-0002-9462-0141
Auvinen, Petri https://orcid.org/0000-0002-3947-4778
Scheperjans, Filip https://orcid.org/0000-0001-9502-7131
El Aidy, Sahar https://orcid.org/0000-0001-8950-4392
-
Funding
Funding for this research was provided by:
Weston Brain Institute
Michael J. Fox Foundation for Parkinson’s Research
Academy of Finland (295724, 310835)
Helsingin ja Uudenmaan Sairaanhoitopiiri (T1010NL101, TYH2018224, TYH2020335)
- License Information
-
More Information
Article History
Received: 7 June 2021
Accepted: 21 November 2021
First Online: 15 December 2021
Competing interests
: F.S. has patents issued (FI127671B and US10139408B2) and pending (US16/186,663 and EP3149205) that are assigned to NeuroBiome Ltd. F.S. is founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd., is a member of the scientific advisory board, and has received consulting fees and stock options from Axial Biotherapeutics. F.S. has received consulting and lecture fees from Orion, Abbvie, Herantis, GE Healthcare, Merck, and Teva. S.E.A. has acquired a research grant from Weston Brain Institute, from which the research of S.P.v.K. is funded. The funders have no role in the preparation of the manuscript.
